Skip to content

Assessment of Different Therapeutic Strategies in Patients With Head and Neck Neoplasms Treated With Radiotherapy

Assessment of Toxicity and Outcomes of Different Therapeutic Strategies in Patients With Head and Neck Neoplasms Treated With Radiotherapy at the IRCCS Azienda Ospedaliero-Universitaria di Bologna

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06773039
Enrollment
3000
Registered
2025-01-14
Start date
2021-10-28
Completion date
2030-12-15
Last updated
2025-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Cancer

Brief summary

This is a monocentric observational study aimed at collecting data related to the radiotherapy treatment of head and neck neoplasms. The purpose of the study is to systematically gather data on radiotherapy for head and neck neoplasms to evaluate tumor response and potential toxicity in relation to dosages and techniques used, the combination with other therapies, disease characteristics, and the psychological impact of the proposed treatments. Additionally, collecting data on both disease characteristics and pre-existing conditions in a large sample may allow for the assessment of any correlation with radiation-induced toxicities, with the goal of predicting and preventing them in a personalized manner in the future. The study's aim is thus to evaluate tumor response and any potential toxicity following radiotherapy treatment concerning treatment modalities, dosages, and techniques used, for both new diagnoses and cases already diagnosed and treated since January 1, 2000, at the Radiotherapy Unit of the S. Orsola-Malpighi Polyclinic. The structured data collection necessary for evaluating the objectives will cover the observation period from January 1, 2000, to December 15, 2030, involving approximately 3,000 patients. Participation in the study solely involves the structured collection of certain information already present in your medical records, as well as data related to clinical exams, radiological imaging, and therapies, without any modifications to standard clinical practice. Participation in the study incurs no costs and will not be compensated in any way. There are no risks or inconveniences associated with participating in this study. Enrolled patients will not receive any direct benefit from this study, as it is purely a data collection effort. The collected data will enhance understanding of the factors associated with treatment outcomes, ultimately leading to improved management of each individual patient.

Detailed description

Head and neck tumors refer to neoplasms that originate in the nasal cavities and paranasal sinuses, rhinopharynx/oropharynx/hypopharynx, salivary glands, oral cavity, and larynx, mostly represented by squamous cell carcinomas. Head and neck tumors account for 4.9% of all malignant tumors worldwide. Treatment is mostly multimodal; the main therapeutic options include surgery, systemic therapy, and radiotherapy. Various treatments may serve as primary or adjuvant therapy depending on the specific neoplasm and the strategy adopted. Regarding radiotherapy, it is often used in combination with other treatments depending on the stage, location of the disease, risk factors, or in a palliative setting. Dosages, fractionation, and techniques vary based on the type of neoplasm being treated and the purpose of the therapy (adjuvant, radical, palliative), as do the possible acute and late toxicities related to the treatment characteristics. The purpose of the study is to systematically collect data related to radiotherapy treatment in head and neck neoplasms in order to evaluate outcomes in relation to dosages, fractionation, and techniques used, as well as combinations with other therapies and disease characteristics. Additionally, collecting data on both disease characteristics and treatments in a large sample may enable the assessment of any potential correlation with radiation-induced toxicities, allowing for future prediction and personalized prevention. Enrolled patients will not have any direct benefit or harm from their participation in the study, as it is solely a data collection effort. Conversely, these data may lead to new insights that improve the management of the analyzed neoplastic diseases in the future. The study thus aims to evaluate outcomes, toxicity, and the psychological impact on patients related to radiotherapy treatment concerning treatment settings, dosages, and techniques used, for both new diagnoses and cases already diagnosed and treated since January 1, 2000, at the Radiotherapy Unit of the S. Orsola Polyclinic. The structured data collection necessary for evaluating the objectives will cover the observation period from January 1, 2000, to December 15, 2030, involving approximately 3,000 patients (2,000 for the retrospective phase and 1,000 for the prospective phase).

Interventions

None listed

Sponsors

IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients of both sexes, aged ≥ 18 years, with new or previous diagnosis of malignant neoplasm of the head and neck, from January 1, 2000, treated at the Radiotherapy Unit of the S. Orsola Polyclinic * Obtaining informed consent

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
Evaluate the correlation of therapy responseFrom enrollment to the last follow-up at 12 monthsEvaluate the correlation of therapy response with other parameters in the radiotherapy treatment of head and neck neoplasms, considering the treatment setting, dosages, and techniques used

Secondary

MeasureTime frameDescription
Late toxicityfrom 6 months after radiotherapy, through study completion, an average of 1 yearlate toxicity after completion of treatments, evaluated according to CTCAE v.5
Impact on the patient's quality of lifeFrom enrollment to the last follow-up at 12 monthsThe impact on patients' quality of life will be assessed through the submission of questionnaires (FACT H&N)
Acute toxicityimmediate to 6 months after radiotherapyacute toxicity after radiotherapy, evaluated according to CTCAE v.5
Disease-free survivalDuring the follow-ups, up to the last one at 12 monthsDisease-free survival assessed based on the presence or absence of local, nodal, or metastatic recurrences
Overall survivalFrom enrollment to the last follow-up at 12 months
RetreatmentsDuring the follow-ups, up to the last one at 12 monthsRetreatments yes or not

Countries

Italy

Contacts

Primary ContactAlessio Giuseppe Morganti, MD
alessio.morganti2@unibo.it+39 0516363136

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026